Annovis Bio, Inc. carries no debt; cash flow comfortably covers obligations.

Annovis Bio, Inc.'s free cash flow has decreased 17.01% from $-21.89B last year to $-25.62B, signaling decreasing performance

Annovis Bio, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Annovis Bio, Inc. has insufficient data to evaluate this check.

Annovis Bio, Inc. has a net cash position, so leverage is healthy.

Annovis Bio, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Annovis Bio, Inc. has insufficient data to evaluate this check.

Annovis Bio, Inc.'s short-term assets of $21.08M exceed its short-term liabilities of $3.64M

Annovis Bio, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Annovis Bio, Inc.'s return on equity of -318.08%, is lower than 15.00%, indicating bad performance

Annovis Bio, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Annovis Bio, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Annovis Bio, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Annovis Bio, Inc. has negative free cash flow, indicating cash burn

Annovis Bio, Inc.'s yearly earnings has decreased 17.34% since last year from $-24.59M to $-28.85M, signaling decreasing performance

Annovis Bio, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -1.20K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Annovis Bio, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Annovis Bio, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Annovis Bio, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Annovis Bio, Inc. is undervalued relative to its fair value price of 748.21 based on Discounted Cash Flow model

Annovis Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Annovis Bio, Inc. is undervalued relative to its fair value price of 982.26 based on EBITDA multiple model

Annovis Bio, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Annovis Bio, Inc. has insufficient data to evaluate this check.

Annovis Bio, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Annovis Bio, Inc. has a price-to-book ratio of 16.83x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Annovis Bio, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue